<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847728</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-234</org_study_id>
    <nct_id>NCT02847728</nct_id>
  </id_info>
  <brief_title>Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice</brief_title>
  <official_title>Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, multicenter study in patients treated with nivolumab for the&#xD;
      approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the&#xD;
      United States (US). Targeted countries in the EU for study participation include Austria,&#xD;
      Belgium, France, Germany, Italy, Spain, Czech Republic, Hungary, Poland and the United&#xD;
      Kingdom (UK). Study objectives are to assess the safety experience, survival, adverse event&#xD;
      management, and outcomes of adverse events associated with nivolumab in routine oncology care&#xD;
      facilities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, multicenter study in patients treated with nivolumab for the&#xD;
      approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the&#xD;
      United States (US). Targeted countries in the EU for study participation include Austria,&#xD;
      Belgium, France, Germany, Italy, Spain, Czech Republic, Hungary, Poland and the United&#xD;
      Kingdom (UK). Study objectives are to assess the safety experience, survival, adverse event&#xD;
      management, and outcomes of adverse events associated with nivolumab in routine oncology care&#xD;
      facilities. The study will be started in 2016, and data collection will be continued until&#xD;
      March 2024.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 31, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related pneumonitis - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related colitis- Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related hepatitis - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related nephritis/renal dysfunction - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related endocrinopathies - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related rash (including toxic epidermal necrolysis) - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of other immune-related adverse events (eg, uveitis, pancreatitis, demyelination, Guillain-Barre Syndrome, myasthenic syndrome, and encephalitis) - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of severe infusion reactions- Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related pneumonitis - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related colitis - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related hepatitis - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related nephritis/renal dysfunction - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related endocrinopathies - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of other immune related adverse events (eg, uveitis, pancreatitis, demyelination, Guillain-Barre Syndrome, myasthenic syndrome, and encephalitis) - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of severe infusion reactions - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related rash (including toxic epidermal necrolysis), - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to nine years</time_frame>
    <description>Other nivolumab treatment-related AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Management of Immune-related AEs:</measure>
    <time_frame>Up to nine years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes of Immune-related AEs:</measure>
    <time_frame>Up to nine years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival:</measure>
    <time_frame>Up to nine years</time_frame>
    <description>1-, 2-, 3-, 4-, and 5-year overall and median survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nivolumab treatment pattern</measure>
    <time_frame>Up to nine years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Melanoma</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm Design</arm_group_label>
    <description>The study encompasses a single arm design with 400 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of 400 adults treated with nivolumab for histologically or&#xD;
        cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically&#xD;
        or cytologically confirmed lung cancer in accordance with the approved indications in&#xD;
        Australia, the EU, Switzerland, and the US. Target EU countries for patient enrollment&#xD;
        include Austria, Belgium, France, Germany, Italy, Spain, Czech Republic, Hungary, Poland&#xD;
        and the UK. Patients who begin treatment with nivolumab for the first time will be enrolled&#xD;
        in accordance with the approved indications and whose treatment strategy was determined&#xD;
        independently from consideration of study participation. Treatment will be determined at&#xD;
        the treating physician's discretion and with the patient's consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of melanoma (including uveal&#xD;
             melanoma) or lung cancer&#xD;
&#xD;
          -  Treatment with commercial nivolumab for the first time, alone or in combination with&#xD;
             ipilimumab, for the approved indications of nivolumab within 14 days before informed&#xD;
             consent for this study OR in the case where treatment has not yet been initiated,&#xD;
             documentation that the treatment strategy is determined before an informed consent to&#xD;
             study participation, and treatment is initiated within 28 days after informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior participation in a clinical trial within the past 4 weeks&#xD;
&#xD;
          -  Previously treated with anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies&#xD;
&#xD;
          -  Previously treated with anti-CTLA-4 for lung cancer&#xD;
&#xD;
          -  Current or pending participation in a clinical trial&#xD;
&#xD;
          -  Current or pending systemic treatment for cancer other than melanoma and lung cancer&#xD;
&#xD;
          -  Inability to comply with the study protocol&#xD;
&#xD;
        Other protocol defined inclusion and exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact sites directly. If there is no contact information,</last_name>
    <phone>Please email:</phone>
    <email>clinical.trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Fortiche, Site: 1909</last_name>
      <phone>760-416-4736</phone>
      <email>Claudia.fortiche@tenethealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Corrales cruz, Site: 1912</last_name>
      <phone>904-427-1217</phone>
      <email>astrid.corralescruz@21co.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lake City Cancer Care, LLC</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanette Strosser, Site: 1907</last_name>
      <phone>386-755-2330</phone>
      <phone_ext>6214</phone_ext>
      <email>slstrosser@ccofnf.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>LaGrange</city>
        <state>Georgia</state>
        <zip>30240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Tolzien, Site: 1901</last_name>
      <phone>847-268-8200</phone>
      <email>shallmeyer@oncmed.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Health St Frances Cabrini Hospital Cancer Center</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Bernadine Norman, Site: 1910</last_name>
      <phone>318-466-6438</phone>
      <email>ramona.norman@christushealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NMMC-Hematology and Oncology Clinic</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Summerford, Site: 1906</last_name>
      <phone>662-377-4550</phone>
      <email>aqsummerford@nmhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System/Overlook Medical Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Peloquin, Site: 1911</last_name>
      <phone>973-971-6298</phone>
      <email>Barbara.peloquin@atlantichealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Center - Anderson</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph's/Candler SC Cancer Specialist</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebbeca McCunn, Site: 1913</last_name>
      <phone>843-689-2895</phone>
      <phone_ext>115</phone_ext>
      <email>mccunnr@sjchs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Beaumont Army Medical Canter</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Abamukong, 1915</last_name>
      <phone>915-742-3432</phone>
      <email>MAbamukong@genevausa.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Smith, Site: 1905</last_name>
      <phone>210-916-3332</phone>
      <email>Peggy.s.smith56.ctr@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Byrne, Site: 1001</last_name>
      <phone>+612 6629 4559</phone>
      <email>sonia.byrne@ncahs.health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wagga Wagga</city>
        <state>New South Wales</state>
        <zip>2650</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari Lashbrook, Site 1002</last_name>
      <phone>+61 2 69321000</phone>
      <email>mlashbrook@riverinacancercare.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Skye Ridley, Site: 1005</last_name>
      <phone>+61 8 6465 9204</phone>
      <email>skye.ridley@sjog.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Donau</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Errhalt, Site: 1101</last_name>
      <phone>+43 2732 9004 - 4360</phone>
      <email>Peter.Errhalt@krems.lknoe.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>InnsBruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Fraidl, Site: 1103</last_name>
      <phone>+43-512-504-81509</phone>
      <email>gabriele.fraidl@tirol-kliniken.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Gallowitsch, Site: 1102</last_name>
      <phone>+43 (0)463 538 DW 31 303</phone>
      <email>Sandra.Gallowitsch@kabeg.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Herman, 1202</last_name>
      <phone>+32 3 650 52 77</phone>
      <email>Datanurse.onco@klina.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Yague, 1201</last_name>
      <phone>+32 81702843</phone>
      <email>caroline.yague@cmsenamur.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika plicnich nemoci Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+420 58 8445657</phone>
      <email>juraj.kultan@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Dr. Juraj Kultan, Site 2002</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomayer Hospital Dept. of Pneumology</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Flavien Devun, Site 1307</last_name>
      <phone>+334 78 86 37 80 (36 37 80)</phone>
      <email>flavien.devun@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sihem Dahou, 1305</last_name>
      <phone>+33 3839 35005</phone>
      <email>s.dahou@oncog.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Lebouc, Site: 1301</last_name>
      <phone>+33 450 637 133</phone>
      <email>mlebouc@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali Gipon, 1304</last_name>
      <phone>+33 04 779 17157</phone>
      <email>Magali.gipon@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore Komperdra, 1303</last_name>
      <phone>+33 5 67 77 17 58</phone>
      <email>komperdra.a@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vandoeuvre-les-Nancy Cedex</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lerchenfeld</city>
        <state>Hamburg</state>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Waldeck, Site: 1424</last_name>
      <phone>+49 40 22 60 46-50</phone>
      <email>r.waldeck@oncoresearch-lerchenfeld.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrike Gravenhorst-Muenter</last_name>
      <phone>+49 40 22 60 46-52</phone>
      <email>u.muenter@oncoresearch-lerchenfeld.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Giessen</city>
        <state>Hesse</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Müller, Site: 1428</last_name>
      <phone>+49 641 985-42604</phone>
      <email>Sharon.Mueller@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Western Pomerania</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ludwigshafen</city>
        <state>Rhineland-Palatinate</state>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Augsburg</city>
        <zip>DE-86179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ballenstedt</city>
        <zip>06493</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bochum</city>
        <zip>5644791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bonn</city>
        <zip>53115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Buergel, Site 1436</last_name>
      <phone>+0049 2241 595423</phone>
      <email>mailto:studienbuero@zaho-rheinland.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bremerhaven</city>
        <zip>27574</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buxtehude</city>
        <zip>DE-21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jena</city>
        <zip>DE-07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kassel</city>
        <zip>DE-34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Lutschkin, Site 1434</last_name>
      <phone>0049 261 921 5693-21</phone>
      <email>j.lutschkin@invo-koblenz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothee Neise, Site: 1415</last_name>
      <phone>+49(0)2151 780 250</phone>
      <email>Neise@Onkologie-Krefeld.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun Klauke, Site: 1419</last_name>
      <phone>+49 (0)0221 8907 13962</phone>
      <email>klaukeg@kliniken-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>155131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minden</city>
        <zip>DE-32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Muenster</city>
        <zip>48157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Munchen</city>
        <zip>DE-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Borgmeier, Site: 1409</last_name>
      <phone>+49 (0)89 4400 - 52590</phone>
      <email>Astrid.Borgmeier@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quedlinburg</city>
        <zip>DE-06484</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Regensburg</city>
        <zip>DE93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Loewigt, Site: 1421</last_name>
      <phone>0049 (0)381-760 1704</phone>
      <email>Loewigt.wk-nord@hotmail.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Martini, 1435</last_name>
      <phone>+0049 (0)681-8576646</phone>
      <email>tanja.martini@onkosaar.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Traunstein</city>
        <zip>383278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ulm</city>
        <zip>23 89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Kirschbaum, Site: 1412</last_name>
      <phone>+49-731-500-45521</phone>
      <email>Rebecca.Kirschbaum@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OKPI Orszagos Koranyi TBC es Pulmonologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+36 20 225-0614</phone>
      <email>drmoldvay@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Judit Moldvay, Site 2104</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orszagos Koranyi Pulm. Intezet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+36 139 132-28</phone>
      <email>afulop64@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Andrea Fulop, Site 2107</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Clinical Centre Departure of Pulmonology- Debreceni Egyetem Klinikai Központ Tüdőgyógyászati Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+36 52 255-222</phone>
      <email>bittner.nora@med.unideb.hu</email>
    </contact>
    <investigator>
      <last_name>Dr. Nora Bittner, Site 2102</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Csongrad Megyei Mellkasi Betegsegek Szakkorhaza</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Tudogyogyintezet Farkasgyepu</name>
      <address>
        <city>Farkasgyepű</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Hospital and University Teaching Hospital Miskolc, Department of Pulmonology</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+36 46 555648</phone>
      <email>ecsanky@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Eszter Csanky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mátrai Gyógyintézet</name>
      <address>
        <city>Mátraháza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pulmonology Hospital Torokbalint</name>
      <address>
        <city>Törökbálint</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+36 23 511-592</phone>
      <email>ggalffy@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Gabriella Galffy, Site 2103</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sant'Andrea Delle Fratte</city>
        <state>Perugia</state>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Colabrese, Site: 1504</last_name>
      <phone>0039 075 5784099</phone>
      <email>d.colabrese@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lucca</city>
        <state>Tuscany</state>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Dalle Mura, Site: 1505</last_name>
      <phone>0039 0583 970161</phone>
      <email>sperimentazione.oncologia@usl2.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O Vito Fazzi -Polo Oncologico</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Annamaria Mauro, Site 1506</last_name>
      <phone>+39 0832 661962</phone>
      <email>mauroannamaria@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrs Michela Spreafico, Site: 1502</last_name>
      <phone>0039 0544 286223</phone>
      <email>michela.spreafico@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojevodzkie Centrum Onkologii u Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+48 58 345-2069</phone>
      <email>mszumska@copernicus.goa.pl</email>
    </contact>
    <investigator>
      <last_name>Dr. Joanna Wojcik-Tomaszewska, Site 2202</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zespół Gruźlicy i Chorób Płuc, Oddzial Onkologii z Pododzialem Chemioterapii</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+48 89 5322978</phone>
      <email>j.kolbsielecki@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Jarosław Kołb-Sielecki, Site 2203</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Opolskie Centrum Onkologii im. Prof. T. Koszarowskiego w Opolu, Oddział Onkologii Klinicznej z Odcinkiem Dziennym</name>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+48 77 441 6088</phone>
      <email>brad@onkologia.opole.pl</email>
    </contact>
    <investigator>
      <last_name>Dr. Barbara Radecka, Site 2201</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Hematology Oncology Group</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Capilla de la Torre, Site:1602</last_name>
      <phone>00349953220306</phone>
      <email>oncojaen@fibao.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Barba, Site: 1601</last_name>
      <phone>+34917878600</phone>
      <phone_ext>2884</phone_ext>
      <email>luis.barba@fundacionmdanderson.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Beatriz Rivas, Site: 1604</last_name>
      <phone>+34923281199</phone>
      <phone_ext>55749</phone_ext>
      <email>brivas@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amalia González, Site: 1603</last_name>
      <phone>0034 925 269200</phone>
      <phone_ext>48632</phone_ext>
      <email>agblazquez@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ávila</city>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena de Francisco, Site: 1606</last_name>
      <phone>+41 81 256 71 65</phone>
      <email>oncoavilacec@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Walter, 1703</last_name>
      <phone>+41 56 486 2765</phone>
      <email>beatrice.walter@ksb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Chikhi, Site: 1702</last_name>
      <phone>+41 91 751 82 30</phone>
      <email>rebecca.chikhi@oncologia-pedrazzini.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB252ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Price, 1803</last_name>
      <phone>+44 1224 554361</phone>
      <email>Nicolaprice@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cornwall</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/safety/recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

